Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
Marketing Status Prescription
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 57237-219; 68071-4964; 50090-2390; 70771-1021; 68071-4959; 50090-4605; 50090-4556; 61919-781; 50090-4780; 50090-2401; 68071-2264; 11532-0011; 68071-2373; 0781-5420; 71335-1298; 68382-306; 70518-2609; 43547-427; 64764-451; 71335-1137; 68071-5155; 68382-307; 60687-391; 33342-056; 57237-221; 72189-293; 68788-7514; 0093-7273; 50090-4586; 70771-1022; 71335-1385; 33342-055; 50090-1321; 68382-308; 16729-020; 70518-2129; 64764-151; 16729-022; 68071-1621; 68788-7511; 0093-7271; 53002-2757; 16729-021; 68071-2437; 70518-2431; 68788-7989; 33342-054; 71335-1659; 0093-7272; 71335-1333; 53002-2755; 71335-0088; 72189-105; 0781-5422; 71335-1759; 70771-1023; 43547-428; 53002-2756; 11532-0013; 68071-5080; 0904-7096; 64764-301; 71610-495; 0904-7090; 70934-619; 0781-5421; 68071-2495; 11532-0012; 57237-220; 43547-426
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lip neoplasm malignant stage unspecified16.13.07.004; 07.21.07.0060.000384%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.000251%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000201%Not Available
Normal newborn18.08.06.0010.000384%Not Available
Metastatic carcinoma of the bladder20.03.04.006; 16.08.01.0040.001103%Not Available
Vitreous adhesions06.09.01.0110.000384%Not Available
Heart injury12.01.11.003; 02.01.01.0100.000384%Not Available
The 8th Page    First    Pre   8    Total 8 Pages